Loading...

Purified anti-human CD28 Antibody Purified anti-human CD28 Antibody

Pricing & Availability
Clone
CD28.2 (See other available formats)
Regulatory Status
RUO
Workshop
V-CD28.05
Other Names
T44, Tp44
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
28.2
Human peripheral blood lymphocytes stained with CD28.2 PE
  • 28.2
    Human peripheral blood lymphocytes stained with CD28.2 PE
Compare all formats
Cat # Size Price Quantity Check Availability Save
302901 25 µg SEK202
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302902 100 µg SEK420
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD28 is a 44 kD disulfide-linked homodimeric type I glycoprotein. It is a member of the immunoglobulin superfamily and is also known as T44 or Tp44. CD28 is expressed on most T lineage cells, NK cell subsets, and plasma cells. CD28 binds both CD80 and CD86 using a highly conserved motif MYPPY in the CDR3-like loop. CD28 is considered a major co-stimulatory molecule, inducing T lymphocyte activation and IL-2 synthesis, and preventing cell death. In vitro studies indicate that ligation of CD28 on T cells by CD80 and CD86 on antigen presenting cells provides a costimulatory signal required for T cell activation and proliferation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Baboon, Capuchin Monkey, Chimpanzee, Pigtailed Macaque, Sooty Mangabey, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F, Costim, FA - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per 106 cells in 100 µl volume or 100 µl whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for highly sensitive assays.

Application References
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Nunes J, et al. 1993. Biochem. J. 293:835.
  3. Calea-Lauri J, et al. 1999. J. Immunol. 163:62.
  4. Tazi A, et al. 1999. J. Immunol. 163:3511. (IHC)
  5. Marti F, et al. 2001. J. Immunol. 166:197. (Costim)
  6. Jeong SH, et al. 2004. J. Virol. 78:6995. (Costim)
  7. Rivollier A, et al. 2004. Blood 104:4029. (Costim)
  8. Scharschmidt E, et al. 2004. Mol. Cell Biol. 24:3860. (Costim)
  9. Sheng W, et al. 2007.Elsevier 580:6819. PubMed
  10. Mitsuhashi M. 2007. Clin Chem.53:148. PubMed
  11. Ye Z, et al. 2008. Infect. Immun. 76:2541. PubMed
  12. Magatti M, et al. 2008. Stem Cells 26:182. (FA) PubMed
  13. Yoshino N, et al. 2008. Exp. Anim. (Tokyo) 49:97. (FC)
  14. Berg M, et al. 2008. J Leukoc Biol. 83:853. (IP) PubMed
  15. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  16. Leonard JA, et al. 2011. J. Virol. 85:6867. PubMed
  17. Nomura T, et al. 2012. J. Virol. 86:6481. PubMed
Product Citations
  1. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  2. Kim SJ, et al. 2020. J Biol Chem. 296:100108. PubMed
  3. Alpert A, et al. 2022. Cell Syst. 13:71. PubMed
  4. Saito T, et al. 2022. ACS Chem Biol. 17:217. PubMed
  5. Toothaker JM, et al. 2022. Development. 149: . PubMed
  6. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  7. Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed
  8. Onnis A, et al. 2023. J Exp Med. 220: . PubMed
  9. Chai H, et al. 2023. Nat Commun. 14:213. PubMed
  10. Poon MML, et al. 2023. Nat Immunol. 24:309. PubMed
  11. Mohamed H, et al. 2023. Biomedicines. 11: . PubMed
  12. Schnizer C 2022. Frontiers in Immunology. 13:1095129. PubMed
  13. Davé E, et al. 2023. MAbs. 15:2160229. PubMed
  14. Pymm P, et al. 2022. Cell Rep. 38:110449. PubMed
  15. Giles JR, et al. 2022. Immunity. 55:557. PubMed
  16. Duan LJ, et al. 2022. Cell Rep. 40:111284. PubMed
  17. Chen L, et al. 2023. Immunology. 169:204. PubMed
  18. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  19. Meadows AM, et al. 2023. iScience. 26:106578. PubMed
  20. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  21. Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed
  22. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  23. Mitsuhashi M 2007. Clin Chem. 53:148. PubMed
  24. Liu L, et al. 2016. Nat Biotechnol. 10.1038/nbt.3461. PubMed
  25. Panigrahi S, et al. 2020. PLoS Pathog. e1008885:16. PubMed
  26. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  27. Zhang Y, et al. 2019. Cell Res. 29:609. PubMed
  28. Friebel E, et al. 2020. Cell. 181(7):1626-1642.e20. PubMed
  29. Zhu Y, et al. 2019. Front Genet. 10:141. PubMed
  30. Ahmed R et al. 2019. Cell. 177(6):1583-1599 . PubMed
  31. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  32. Zucchetti AE, et al. 2019. Nat Commun. 10:2864. PubMed
  33. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  34. Taft J, et al. 2021. Cell. 184(17):4447-4463.e20. PubMed
  35. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  36. Tocheva AS, et al. 2020. J Biol Chem. 295:18036. PubMed
  37. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  38. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  39. Fasbender F, et al. 2017. Front Immunol. 0.88125. PubMed
  40. Willimsky G, et al. 2021. Elife. 10:. PubMed
  41. Song C, et al. 2022. Stem Cell Res Ther. 13:48. PubMed
  42. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  43. Bobardt M, et al. 2020. PLoS One. 15:e0227715. PubMed
  44. Haas R, et al. 2015. PLoS Biol. 13: 1002202. PubMed
  45. Ye Z, et al. 2008. Infect Immun. 76:2541. PubMed
  46. Woolsey C, et al. 2020. Scientific Reports. 10(1):3071.. PubMed
  47. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  48. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  49. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  50. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  51. Kondo H, et al. 2022. Front Immunol. 13:836923. PubMed
  52. Dias J, et al. 2018. Proc Natl Acad Sci U S A. 115:E11513. PubMed
  53. Oberg HH, et al. 2020. J Leukoc Biol. 107:1081. PubMed
  54. Gaa R, et al. 2021. MAbs. 13:1978130. PubMed
  55. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  56. Meléndez AV, et al. 2022. Cell Mol Life Sci. 79:513. PubMed
  57. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  58. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  59. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  60. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  61. O'Boyle KC, et al. 2020. Methods Mol Biol. 2111:1. PubMed
  62. Guo T, et al. 2018. J Immunol. 200:500. PubMed
  63. Jin H, et al. 2019. MBio. 10:e01769-19. PubMed
  64. Jimenez RV, et al. 2019. Front Immunol. 1.932638889. PubMed
  65. Cai J, et al. 2021. eLife. 10:00. PubMed
  66. Liu Y, et al. 2022. Micromachines (Basel). 13:. PubMed
  67. Zhu Y, et al. 2019. Cell Stem Cell. 25:542. PubMed
  68. Kinosada H, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006120. PubMed
  69. Ito T, et al. 2021. Commun Biol. 4:694. PubMed
  70. Jakob M, et al. 2020. Cells. 10:. PubMed
  71. Tocheva AS, et al. 2020. J Biol Chem. 295:18036. PubMed
  72. Sattler A, et al. 2021. Am J Transplant. 21:87. PubMed
  73. Leonard J, et al. 2011. J Virol. 85:6867. PubMed
  74. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  75. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  76. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  77. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  78. Pardons M, et al. 2019. PLoS Pathog. 15:e1007619. PubMed
  79. Gee MH, et al. 2018. Cell. 172:549. PubMed
  80. Bonavia AS, et al. 2022. Front Immunol. 13:940030. PubMed
  81. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  82. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  83. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  84. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  85. Duque JSR, et al. 2022. Nat Commun. 13:3700. PubMed
  86. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  87. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  88. Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed
  89. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  90. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  91. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  92. Sheng WY, et al. 2006. FEBS Lett. 580:6819. PubMed
  93. Naranbhai V, et al. 2022. Cell. . PubMed
  94. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  95. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  96. Mazer M, et al. 2019. J Immunol. 203:2088. PubMed
  97. Nomura T, et al. 2012. J Virol. 86:6481. PubMed
  98. Jones N, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01516. PubMed
  99. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  100. He Y, et al. 2021. eLife. 10:00. PubMed
  101. Ren X, et al. 2021. Lab Chip. 21:1527. PubMed
  102. Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed
  103. Ravell JC, et al. 2020. J Clin Invest. 130:507. PubMed
  104. Bantug GR, et al. 2018. Immunity. 48:542. PubMed
  105. Umeda M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  106. Martin E, et al. 2020. JCI Insight. :5. PubMed
  107. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  108. Kim SJ, et al. 2020. J Biol Chem. 296:100108. PubMed
  109. Alpert A, et al. 2022. Cell Syst. 13:71. PubMed
  110. Saito T, et al. 2022. ACS Chem Biol. 17:217. PubMed
  111. Toothaker JM, et al. 2022. Development. 149: . PubMed
  112. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  113. Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed
  114. Onnis A, et al. 2023. J Exp Med. 220: . PubMed
  115. Chai H, et al. 2023. Nat Commun. 14:213. PubMed
  116. Poon MML, et al. 2023. Nat Immunol. 24:309. PubMed
  117. Mohamed H, et al. 2023. Biomedicines. 11: . PubMed
  118. Schnizer C 2022. Frontiers in Immunology. 13:1095129. PubMed
  119. Davé E, et al. 2023. MAbs. 15:2160229. PubMed
  120. Pymm P, et al. 2022. Cell Rep. 38:110449. PubMed
  121. Giles JR, et al. 2022. Immunity. 55:557. PubMed
  122. Duan LJ, et al. 2022. Cell Rep. 40:111284. PubMed
  123. Chen L, et al. 2023. Immunology. 169:204. PubMed
  124. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  125. Meadows AM, et al. 2023. iScience. 26:106578. PubMed
  126. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  127. Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed
  128. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  129. Mitsuhashi M 2007. Clin Chem. 53:148. PubMed
  130. Liu L, et al. 2016. Nat Biotechnol. 10.1038/nbt.3461. PubMed
  131. Panigrahi S, et al. 2020. PLoS Pathog. e1008885:16. PubMed
  132. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  133. Zhang Y, et al. 2019. Cell Res. 29:609. PubMed
  134. Friebel E, et al. 2020. Cell. 181(7):1626-1642.e20. PubMed
  135. Zhu Y, et al. 2019. Front Genet. 10:141. PubMed
  136. Ahmed R et al. 2019. Cell. 177(6):1583-1599 . PubMed
  137. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  138. Zucchetti AE, et al. 2019. Nat Commun. 10:2864. PubMed
  139. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  140. Taft J, et al. 2021. Cell. 184(17):4447-4463.e20. PubMed
  141. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  142. Tocheva AS, et al. 2020. J Biol Chem. 295:18036. PubMed
  143. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  144. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  145. Fasbender F, et al. 2017. Front Immunol. 0.88125. PubMed
  146. Willimsky G, et al. 2021. Elife. 10:. PubMed
  147. Song C, et al. 2022. Stem Cell Res Ther. 13:48. PubMed
  148. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  149. Bobardt M, et al. 2020. PLoS One. 15:e0227715. PubMed
  150. Haas R, et al. 2015. PLoS Biol. 13: 1002202. PubMed
  151. Ye Z, et al. 2008. Infect Immun. 76:2541. PubMed
  152. Woolsey C, et al. 2020. Scientific Reports. 10(1):3071.. PubMed
  153. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  154. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  155. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  156. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  157. Kondo H, et al. 2022. Front Immunol. 13:836923. PubMed
  158. Dias J, et al. 2018. Proc Natl Acad Sci U S A. 115:E11513. PubMed
  159. Oberg HH, et al. 2020. J Leukoc Biol. 107:1081. PubMed
  160. Gaa R, et al. 2021. MAbs. 13:1978130. PubMed
  161. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  162. Meléndez AV, et al. 2022. Cell Mol Life Sci. 79:513. PubMed
  163. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  164. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  165. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  166. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  167. O'Boyle KC, et al. 2020. Methods Mol Biol. 2111:1. PubMed
  168. Guo T, et al. 2018. J Immunol. 200:500. PubMed
  169. Jin H, et al. 2019. MBio. 10:e01769-19. PubMed
  170. Jimenez RV, et al. 2019. Front Immunol. 1.932638889. PubMed
  171. Cai J, et al. 2021. eLife. 10:00. PubMed
  172. Liu Y, et al. 2022. Micromachines (Basel). 13:. PubMed
  173. Zhu Y, et al. 2019. Cell Stem Cell. 25:542. PubMed
  174. Kinosada H, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006120. PubMed
  175. Ito T, et al. 2021. Commun Biol. 4:694. PubMed
  176. Jakob M, et al. 2020. Cells. 10:. PubMed
  177. Tocheva AS, et al. 2020. J Biol Chem. 295:18036. PubMed
  178. Sattler A, et al. 2021. Am J Transplant. 21:87. PubMed
  179. Leonard J, et al. 2011. J Virol. 85:6867. PubMed
  180. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  181. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  182. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  183. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  184. Pardons M, et al. 2019. PLoS Pathog. 15:e1007619. PubMed
  185. Gee MH, et al. 2018. Cell. 172:549. PubMed
  186. Bonavia AS, et al. 2022. Front Immunol. 13:940030. PubMed
  187. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  188. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  189. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  190. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  191. Duque JSR, et al. 2022. Nat Commun. 13:3700. PubMed
  192. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  193. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  194. Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed
  195. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  196. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  197. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  198. Sheng WY, et al. 2006. FEBS Lett. 580:6819. PubMed
  199. Naranbhai V, et al. 2022. Cell. . PubMed
  200. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  201. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  202. Mazer M, et al. 2019. J Immunol. 203:2088. PubMed
  203. Nomura T, et al. 2012. J Virol. 86:6481. PubMed
  204. Jones N, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01516. PubMed
  205. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  206. He Y, et al. 2021. eLife. 10:00. PubMed
  207. Ren X, et al. 2021. Lab Chip. 21:1527. PubMed
  208. Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed
  209. Ravell JC, et al. 2020. J Clin Invest. 130:507. PubMed
  210. Bantug GR, et al. 2018. Immunity. 48:542. PubMed
  211. Umeda M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  212. Martin E, et al. 2020. JCI Insight. :5. PubMed
RRID
AB_314303 (BioLegend Cat. No. 302901)
AB_314304 (BioLegend Cat. No. 302902)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, homodimer, 44 kD
Distribution

Mature T cells, thymocytes, NK cell subsets, plasma cells, EBV-positive B cells

Function
T cell costimulation
Ligand/Receptor
CD80, CD86
Cell Type
B cells, NK cells, Plasma cells, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. June CH, et al. 1994. Immunol. Today 15:321.
3. Linskey PS, et al. 1993. Annu. Rev. Immunol. 11:191.

Gene ID
940 View all products for this Gene ID
UniProt
View information about CD28 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD28 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-human CD28 (Maxpar® Ready) CD28.2 FC,CyTOF®
PE/Dazzle™ 594 anti-human CD28 CD28.2 FC
Brilliant Violet 785™ anti-human CD28 CD28.2 FC
Brilliant Violet 650™ anti-human CD28 CD28.2 FC
Brilliant Violet 711™ anti-human CD28 CD28.2 FC
APC/Fire™ 750 anti-human CD28 CD28.2 FC
Alexa Fluor® 647 anti-human CD28 CD28.2 FC
TotalSeq™-C0386 anti-human CD28 CD28.2 PG
Brilliant Violet 605™ anti-human CD28 CD28.2 FC
APC/Cyanine7 anti-human CD28 CD28.2 FC
TotalSeq™-B0386 anti-human CD28 CD28.2 PG
TotalSeq™-A0386 anti-human CD28 CD28.2 PG
PE anti-human CD28 CD28.2 FC
APC anti-human CD28 CD28.2 FC
Brilliant Violet 750™ anti-human CD28 CD28.2 FC
APC anti-human CD28 CD28.2 FC
Biotin anti-human CD28 CD28.2 FC
FITC anti-human CD28 CD28.2 FC
PE anti-human CD28 CD28.2 FC
PE/Cyanine5 anti-human CD28 CD28.2 FC
Purified anti-human CD28 CD28.2 FC,IHC-F,Costim,FA
Alexa Fluor® 488 anti-human CD28 CD28.2 FC
Alexa Fluor® 700 anti-human CD28 CD28.2 FC
PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Pacific Blue™ anti-human CD28 CD28.2 FC
PE/Cyanine7 anti-human CD28 CD28.2 FC
Ultra-LEAF™ Purified anti-human CD28 CD28.2 FC,IHC-F,Costim,FA
Brilliant Violet 421™ anti-human CD28 CD28.2 FC
Brilliant Violet 510™ anti-human CD28 CD28.2 FC
PE/Fire™ 810 anti-human CD28 CD28.2 FC
TotalSeq™-D0386 anti-human CD28 CD28.2 PG
Spark Violet™ 423 anti-human CD28 CD28.2 FC
GMP PE anti-human CD28 CD28.2 FC
Cell-Vive™ GMP Ultra-LEAF™ Purified anti-human CD28 SF CD28.2 FC,Costim
GMP APC anti-human CD28 CD28.2 FC
PE/Cyanine7 anti-human CD28 CD28.2 FC
Cell-Vive™ GMP Ultra-LEAF™ Biotin anti-human CD28 SF CD28.2 FC,Activ
PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Spark Blue™ 515 anti-human CD28 CD28.2 FC
Spark Red™ 718 anti-human CD28 CD28.2 FC
GMP PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Pacific Blue™ anti-human CD28 CD28.2 FC
APC/Fire™ 810 anti-human CD28 CD28.2 FC
Spark YG™ 581 anti-human CD28 (Flexi-Fluor™) CD28.2 FC
Spark YG™ 593 anti-human CD28 (Flexi-Fluor™) Antibody CD28.2 FC
Spark NIR™ 685 anti-human CD28 (Flexi-Fluor™) Antibody CD28.2 FC
Spark UV™ 387 anti-human CD28 (Flexi-Fluor™) CD28.2 FC
Go To Top Version: 3    Revision Date: 08-25-2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
CD28.2 (See other available formats)
Regulatory Status
RUO
Workshop
V-CD28.05
Other Names
T44, Tp44
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
28.2
Human peripheral blood lymphocytes stained with CD28.2 PE
  • 28.2
    Human peripheral blood lymphocytes stained with CD28.2 PE
Compare all formats
Cat # Size Price Quantity Check Availability Save
302901 25 µg SEK202
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302902 100 µg SEK420
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD28 is a 44 kD disulfide-linked homodimeric type I glycoprotein. It is a member of the immunoglobulin superfamily and is also known as T44 or Tp44. CD28 is expressed on most T lineage cells, NK cell subsets, and plasma cells. CD28 binds both CD80 and CD86 using a highly conserved motif MYPPY in the CDR3-like loop. CD28 is considered a major co-stimulatory molecule, inducing T lymphocyte activation and IL-2 synthesis, and preventing cell death. In vitro studies indicate that ligation of CD28 on T cells by CD80 and CD86 on antigen presenting cells provides a costimulatory signal required for T cell activation and proliferation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Baboon, Capuchin Monkey, Chimpanzee, Pigtailed Macaque, Sooty Mangabey, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F, Costim, FA - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per 106 cells in 100 µl volume or 100 µl whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for highly sensitive assays.

Application References
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Nunes J, et al. 1993. Biochem. J. 293:835.
  3. Calea-Lauri J, et al. 1999. J. Immunol. 163:62.
  4. Tazi A, et al. 1999. J. Immunol. 163:3511. (IHC)
  5. Marti F, et al. 2001. J. Immunol. 166:197. (Costim)
  6. Jeong SH, et al. 2004. J. Virol. 78:6995. (Costim)
  7. Rivollier A, et al. 2004. Blood 104:4029. (Costim)
  8. Scharschmidt E, et al. 2004. Mol. Cell Biol. 24:3860. (Costim)
  9. Sheng W, et al. 2007.Elsevier 580:6819. PubMed
  10. Mitsuhashi M. 2007. Clin Chem.53:148. PubMed
  11. Ye Z, et al. 2008. Infect. Immun. 76:2541. PubMed
  12. Magatti M, et al. 2008. Stem Cells 26:182. (FA) PubMed
  13. Yoshino N, et al. 2008. Exp. Anim. (Tokyo) 49:97. (FC)
  14. Berg M, et al. 2008. J Leukoc Biol. 83:853. (IP) PubMed
  15. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  16. Leonard JA, et al. 2011. J. Virol. 85:6867. PubMed
  17. Nomura T, et al. 2012. J. Virol. 86:6481. PubMed
Product Citations
  1. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  2. Kim SJ, et al. 2020. J Biol Chem. 296:100108. PubMed
  3. Alpert A, et al. 2022. Cell Syst. 13:71. PubMed
  4. Saito T, et al. 2022. ACS Chem Biol. 17:217. PubMed
  5. Toothaker JM, et al. 2022. Development. 149: . PubMed
  6. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  7. Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed
  8. Onnis A, et al. 2023. J Exp Med. 220: . PubMed
  9. Chai H, et al. 2023. Nat Commun. 14:213. PubMed
  10. Poon MML, et al. 2023. Nat Immunol. 24:309. PubMed
  11. Mohamed H, et al. 2023. Biomedicines. 11: . PubMed
  12. Schnizer C 2022. Frontiers in Immunology. 13:1095129. PubMed
  13. Davé E, et al. 2023. MAbs. 15:2160229. PubMed
  14. Pymm P, et al. 2022. Cell Rep. 38:110449. PubMed
  15. Giles JR, et al. 2022. Immunity. 55:557. PubMed
  16. Duan LJ, et al. 2022. Cell Rep. 40:111284. PubMed
  17. Chen L, et al. 2023. Immunology. 169:204. PubMed
  18. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  19. Meadows AM, et al. 2023. iScience. 26:106578. PubMed
  20. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  21. Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed
  22. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  23. Mitsuhashi M 2007. Clin Chem. 53:148. PubMed
  24. Liu L, et al. 2016. Nat Biotechnol. 10.1038/nbt.3461. PubMed
  25. Panigrahi S, et al. 2020. PLoS Pathog. e1008885:16. PubMed
  26. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  27. Zhang Y, et al. 2019. Cell Res. 29:609. PubMed
  28. Friebel E, et al. 2020. Cell. 181(7):1626-1642.e20. PubMed
  29. Zhu Y, et al. 2019. Front Genet. 10:141. PubMed
  30. Ahmed R et al. 2019. Cell. 177(6):1583-1599 . PubMed
  31. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  32. Zucchetti AE, et al. 2019. Nat Commun. 10:2864. PubMed
  33. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  34. Taft J, et al. 2021. Cell. 184(17):4447-4463.e20. PubMed
  35. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  36. Tocheva AS, et al. 2020. J Biol Chem. 295:18036. PubMed
  37. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  38. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  39. Fasbender F, et al. 2017. Front Immunol. 0.88125. PubMed
  40. Willimsky G, et al. 2021. Elife. 10:. PubMed
  41. Song C, et al. 2022. Stem Cell Res Ther. 13:48. PubMed
  42. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  43. Bobardt M, et al. 2020. PLoS One. 15:e0227715. PubMed
  44. Haas R, et al. 2015. PLoS Biol. 13: 1002202. PubMed
  45. Ye Z, et al. 2008. Infect Immun. 76:2541. PubMed
  46. Woolsey C, et al. 2020. Scientific Reports. 10(1):3071.. PubMed
  47. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  48. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  49. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  50. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  51. Kondo H, et al. 2022. Front Immunol. 13:836923. PubMed
  52. Dias J, et al. 2018. Proc Natl Acad Sci U S A. 115:E11513. PubMed
  53. Oberg HH, et al. 2020. J Leukoc Biol. 107:1081. PubMed
  54. Gaa R, et al. 2021. MAbs. 13:1978130. PubMed
  55. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  56. Meléndez AV, et al. 2022. Cell Mol Life Sci. 79:513. PubMed
  57. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  58. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  59. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  60. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  61. O'Boyle KC, et al. 2020. Methods Mol Biol. 2111:1. PubMed
  62. Guo T, et al. 2018. J Immunol. 200:500. PubMed
  63. Jin H, et al. 2019. MBio. 10:e01769-19. PubMed
  64. Jimenez RV, et al. 2019. Front Immunol. 1.932638889. PubMed
  65. Cai J, et al. 2021. eLife. 10:00. PubMed
  66. Liu Y, et al. 2022. Micromachines (Basel). 13:. PubMed
  67. Zhu Y, et al. 2019. Cell Stem Cell. 25:542. PubMed
  68. Kinosada H, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006120. PubMed
  69. Ito T, et al. 2021. Commun Biol. 4:694. PubMed
  70. Jakob M, et al. 2020. Cells. 10:. PubMed
  71. Tocheva AS, et al. 2020. J Biol Chem. 295:18036. PubMed
  72. Sattler A, et al. 2021. Am J Transplant. 21:87. PubMed
  73. Leonard J, et al. 2011. J Virol. 85:6867. PubMed
  74. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  75. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  76. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  77. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  78. Pardons M, et al. 2019. PLoS Pathog. 15:e1007619. PubMed
  79. Gee MH, et al. 2018. Cell. 172:549. PubMed
  80. Bonavia AS, et al. 2022. Front Immunol. 13:940030. PubMed
  81. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  82. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  83. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  84. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  85. Duque JSR, et al. 2022. Nat Commun. 13:3700. PubMed
  86. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  87. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  88. Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed
  89. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  90. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  91. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  92. Sheng WY, et al. 2006. FEBS Lett. 580:6819. PubMed
  93. Naranbhai V, et al. 2022. Cell. . PubMed
  94. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  95. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  96. Mazer M, et al. 2019. J Immunol. 203:2088. PubMed
  97. Nomura T, et al. 2012. J Virol. 86:6481. PubMed
  98. Jones N, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01516. PubMed
  99. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  100. He Y, et al. 2021. eLife. 10:00. PubMed
  101. Ren X, et al. 2021. Lab Chip. 21:1527. PubMed
  102. Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed
  103. Ravell JC, et al. 2020. J Clin Invest. 130:507. PubMed
  104. Bantug GR, et al. 2018. Immunity. 48:542. PubMed
  105. Umeda M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  106. Martin E, et al. 2020. JCI Insight. :5. PubMed
  107. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  108. Kim SJ, et al. 2020. J Biol Chem. 296:100108. PubMed
  109. Alpert A, et al. 2022. Cell Syst. 13:71. PubMed
  110. Saito T, et al. 2022. ACS Chem Biol. 17:217. PubMed
  111. Toothaker JM, et al. 2022. Development. 149: . PubMed
  112. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  113. Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed
  114. Onnis A, et al. 2023. J Exp Med. 220: . PubMed
  115. Chai H, et al. 2023. Nat Commun. 14:213. PubMed
  116. Poon MML, et al. 2023. Nat Immunol. 24:309. PubMed
  117. Mohamed H, et al. 2023. Biomedicines. 11: . PubMed
  118. Schnizer C 2022. Frontiers in Immunology. 13:1095129. PubMed
  119. Davé E, et al. 2023. MAbs. 15:2160229. PubMed
  120. Pymm P, et al. 2022. Cell Rep. 38:110449. PubMed
  121. Giles JR, et al. 2022. Immunity. 55:557. PubMed
  122. Duan LJ, et al. 2022. Cell Rep. 40:111284. PubMed
  123. Chen L, et al. 2023. Immunology. 169:204. PubMed
  124. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  125. Meadows AM, et al. 2023. iScience. 26:106578. PubMed
  126. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  127. Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed
  128. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  129. Mitsuhashi M 2007. Clin Chem. 53:148. PubMed
  130. Liu L, et al. 2016. Nat Biotechnol. 10.1038/nbt.3461. PubMed
  131. Panigrahi S, et al. 2020. PLoS Pathog. e1008885:16. PubMed
  132. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  133. Zhang Y, et al. 2019. Cell Res. 29:609. PubMed
  134. Friebel E, et al. 2020. Cell. 181(7):1626-1642.e20. PubMed
  135. Zhu Y, et al. 2019. Front Genet. 10:141. PubMed
  136. Ahmed R et al. 2019. Cell. 177(6):1583-1599 . PubMed
  137. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  138. Zucchetti AE, et al. 2019. Nat Commun. 10:2864. PubMed
  139. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  140. Taft J, et al. 2021. Cell. 184(17):4447-4463.e20. PubMed
  141. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  142. Tocheva AS, et al. 2020. J Biol Chem. 295:18036. PubMed
  143. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  144. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  145. Fasbender F, et al. 2017. Front Immunol. 0.88125. PubMed
  146. Willimsky G, et al. 2021. Elife. 10:. PubMed
  147. Song C, et al. 2022. Stem Cell Res Ther. 13:48. PubMed
  148. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  149. Bobardt M, et al. 2020. PLoS One. 15:e0227715. PubMed
  150. Haas R, et al. 2015. PLoS Biol. 13: 1002202. PubMed
  151. Ye Z, et al. 2008. Infect Immun. 76:2541. PubMed
  152. Woolsey C, et al. 2020. Scientific Reports. 10(1):3071.. PubMed
  153. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  154. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  155. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  156. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  157. Kondo H, et al. 2022. Front Immunol. 13:836923. PubMed
  158. Dias J, et al. 2018. Proc Natl Acad Sci U S A. 115:E11513. PubMed
  159. Oberg HH, et al. 2020. J Leukoc Biol. 107:1081. PubMed
  160. Gaa R, et al. 2021. MAbs. 13:1978130. PubMed
  161. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  162. Meléndez AV, et al. 2022. Cell Mol Life Sci. 79:513. PubMed
  163. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  164. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  165. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  166. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  167. O'Boyle KC, et al. 2020. Methods Mol Biol. 2111:1. PubMed
  168. Guo T, et al. 2018. J Immunol. 200:500. PubMed
  169. Jin H, et al. 2019. MBio. 10:e01769-19. PubMed
  170. Jimenez RV, et al. 2019. Front Immunol. 1.932638889. PubMed
  171. Cai J, et al. 2021. eLife. 10:00. PubMed
  172. Liu Y, et al. 2022. Micromachines (Basel). 13:. PubMed
  173. Zhu Y, et al. 2019. Cell Stem Cell. 25:542. PubMed
  174. Kinosada H, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006120. PubMed
  175. Ito T, et al. 2021. Commun Biol. 4:694. PubMed
  176. Jakob M, et al. 2020. Cells. 10:. PubMed
  177. Tocheva AS, et al. 2020. J Biol Chem. 295:18036. PubMed
  178. Sattler A, et al. 2021. Am J Transplant. 21:87. PubMed
  179. Leonard J, et al. 2011. J Virol. 85:6867. PubMed
  180. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  181. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  182. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  183. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  184. Pardons M, et al. 2019. PLoS Pathog. 15:e1007619. PubMed
  185. Gee MH, et al. 2018. Cell. 172:549. PubMed
  186. Bonavia AS, et al. 2022. Front Immunol. 13:940030. PubMed
  187. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  188. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  189. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  190. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  191. Duque JSR, et al. 2022. Nat Commun. 13:3700. PubMed
  192. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  193. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  194. Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed
  195. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  196. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  197. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  198. Sheng WY, et al. 2006. FEBS Lett. 580:6819. PubMed
  199. Naranbhai V, et al. 2022. Cell. . PubMed
  200. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  201. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  202. Mazer M, et al. 2019. J Immunol. 203:2088. PubMed
  203. Nomura T, et al. 2012. J Virol. 86:6481. PubMed
  204. Jones N, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01516. PubMed
  205. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  206. He Y, et al. 2021. eLife. 10:00. PubMed
  207. Ren X, et al. 2021. Lab Chip. 21:1527. PubMed
  208. Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed
  209. Ravell JC, et al. 2020. J Clin Invest. 130:507. PubMed
  210. Bantug GR, et al. 2018. Immunity. 48:542. PubMed
  211. Umeda M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  212. Martin E, et al. 2020. JCI Insight. :5. PubMed
RRID
AB_314303 (BioLegend Cat. No. 302901)
AB_314304 (BioLegend Cat. No. 302902)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, homodimer, 44 kD
Distribution

Mature T cells, thymocytes, NK cell subsets, plasma cells, EBV-positive B cells

Function
T cell costimulation
Ligand/Receptor
CD80, CD86
Cell Type
B cells, NK cells, Plasma cells, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. June CH, et al. 1994. Immunol. Today 15:321.
3. Linskey PS, et al. 1993. Annu. Rev. Immunol. 11:191.

Gene ID
940 View all products for this Gene ID
UniProt
View information about CD28 on UniProt.org

Other Formats

View All CD28 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-human CD28 (Maxpar® Ready) CD28.2 FC,CyTOF®
PE/Dazzle™ 594 anti-human CD28 CD28.2 FC
Brilliant Violet 785™ anti-human CD28 CD28.2 FC
Brilliant Violet 650™ anti-human CD28 CD28.2 FC
Brilliant Violet 711™ anti-human CD28 CD28.2 FC
APC/Fire™ 750 anti-human CD28 CD28.2 FC
Alexa Fluor® 647 anti-human CD28 CD28.2 FC
TotalSeq™-C0386 anti-human CD28 CD28.2 PG
Brilliant Violet 605™ anti-human CD28 CD28.2 FC
APC/Cyanine7 anti-human CD28 CD28.2 FC
TotalSeq™-B0386 anti-human CD28 CD28.2 PG
TotalSeq™-A0386 anti-human CD28 CD28.2 PG
PE anti-human CD28 CD28.2 FC
APC anti-human CD28 CD28.2 FC
Brilliant Violet 750™ anti-human CD28 CD28.2 FC
APC anti-human CD28 CD28.2 FC
Biotin anti-human CD28 CD28.2 FC
FITC anti-human CD28 CD28.2 FC
PE anti-human CD28 CD28.2 FC
PE/Cyanine5 anti-human CD28 CD28.2 FC
Purified anti-human CD28 CD28.2 FC,IHC-F,Costim,FA
Alexa Fluor® 488 anti-human CD28 CD28.2 FC
Alexa Fluor® 700 anti-human CD28 CD28.2 FC
PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Pacific Blue™ anti-human CD28 CD28.2 FC
PE/Cyanine7 anti-human CD28 CD28.2 FC
Ultra-LEAF™ Purified anti-human CD28 CD28.2 FC,IHC-F,Costim,FA
Brilliant Violet 421™ anti-human CD28 CD28.2 FC
Brilliant Violet 510™ anti-human CD28 CD28.2 FC
PE/Fire™ 810 anti-human CD28 CD28.2 FC
TotalSeq™-D0386 anti-human CD28 CD28.2 PG
Spark Violet™ 423 anti-human CD28 CD28.2 FC
GMP PE anti-human CD28 CD28.2 FC
Cell-Vive™ GMP Ultra-LEAF™ Purified anti-human CD28 SF CD28.2 FC,Costim
GMP APC anti-human CD28 CD28.2 FC
PE/Cyanine7 anti-human CD28 CD28.2 FC
Cell-Vive™ GMP Ultra-LEAF™ Biotin anti-human CD28 SF CD28.2 FC,Activ
PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Spark Blue™ 515 anti-human CD28 CD28.2 FC
Spark Red™ 718 anti-human CD28 CD28.2 FC
GMP PerCP/Cyanine5.5 anti-human CD28 CD28.2 FC
Pacific Blue™ anti-human CD28 CD28.2 FC
APC/Fire™ 810 anti-human CD28 CD28.2 FC
Spark YG™ 581 anti-human CD28 (Flexi-Fluor™) CD28.2 FC
Spark YG™ 593 anti-human CD28 (Flexi-Fluor™) Antibody CD28.2 FC
Spark NIR™ 685 anti-human CD28 (Flexi-Fluor™) Antibody CD28.2 FC
Spark UV™ 387 anti-human CD28 (Flexi-Fluor™) CD28.2 FC
Go To Top Version: 3    Revision Date: 08-25-2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account